AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00062647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin, nafcillin, oxacillin, or cloxacillin
Description: Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.
Study NCT00033371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Given 400 mg PO twice a day
Study NCT00033371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given 400 mg PO twice a day
Study NCT00033371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO to match DFMO
Study NCT00033371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eflornithine
Description: Given PO at 0.5 gm/m\^2/day rounded down to the nearest 250 mg dose (BSA of \< 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of > 2.6 = 1,250 mg/day).
Study NCT00033371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study NCT00033371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study NCT00033371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT00033371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT02883426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)
Description: Approximately 10\^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally
Study NCT02883426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3N2v inactivated subvirion influenza vaccine
Description: 15 μg; administered intramuscularly
Study NCT02883426 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H3N2v inactivated subvirion influenza vaccine
Description: 15 μg; administered intramuscularly
Study NCT02883426 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by nasal spray
Study NCT00601679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NT-proBNP guided care
Description: knowledge of NT-proBNP results
Study NCT01847690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Cortef 5 mg tablets per os, 2x5 mg, one day, one time
Study NCT03290794 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Intravitreal Aflibercept as prescribed by the treating Physician
Study NCT01512472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: degarelix
Description: Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
Study NCT05906667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sharing History through Active Reminiscence and Photo-imagery (SHARP)
Description: Participants engage in neighborhood walks and conversational reminisce three times per week over 24 weeks
Study NCT01444872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV120027
Description: IV infusion
Study NCT01444872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: IV infusion
Study NCT01475318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: 200 mg mifepristone on day 1
Study NCT01475318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 10mg PO on day 1, day 2, and day 3
Study NCT01475318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: misoprostol 800mcg PV on day 3
Study NCT03446001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237 16 mg/day
Description: Oral TRx0237 4-mg tablets administered twice daily
Study NCT03446001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily
Study NCT03446001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237 8 mg/day
Description: Oral TRx0237 4-mg tablet administered twice daily
Study NCT03012542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet 1
Description: Diet controlled in amount and source of carbohydrates or fiber containing foods.
Study NCT03012542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet 2
Description: Diet controlled in amount and source of carbohydrates or fiber containing foods.
Study NCT02508519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: An acupuncture needle insertion according to zonal or balance method.
Study NCT00524043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 1.5 mg tablet once daily for 6 weeks
Study NCT00524043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily for 6 weeks
Study NCT00524043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone ER
Description: 6 mg tablet once daily for 6 weeks
Study NCT01335490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cook stoves, either Biolite wood stove, or liquified petroleum gas stove plus fuel
Description: The cooking stoves will reduce air emissions significantly in the home, resulting in improved infant health. It will be given to the mother in the second or third trimester.
Study NCT01499797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The CareWell programme
Description: The CareWell programme contains the following components:~* multidisciplinary primary care teams~* working with proactive care plans integrating cure, care and welfare~* advanced care planning (e.g. recording limitations of treatment, non-resuscitation decisions)~* medication review~* case-management~* guidelines for consultation of in-hospital geriatric experts~* guidelines for transfers from primary care to home-based facilities and hospital and back~* practice guidelines for management of common geriatric conditions
Study NCT00513994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP
Study NCT03175016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to restrict a tumor's blood supply.
Study NCT03175016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.
Study NCT03175016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eluting-bead
Description: The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
Study NCT04776915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound and Hysterosalpingography
Description: Ultrasound and Hysterosalpingography
Study NCT00396305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sterile phosphate buffered saline solution.
Study NCT00396305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza
Description: The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.
Study NCT00701246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferrous sulfate
Study NCT00701246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ferrous sulfate
Study NCT00701246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Study NCT00701246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (folic acid)
Study NCT00865046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periosteal stimulation
Description: Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.
Study NCT00865046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Periosteal stimulation
Description: Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.
Study NCT00865046 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control-Periosteal Stimulation
Description: Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.
Study NCT00865046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control-Periosteal Stimulation
Description: Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.
Study NCT03892707 — intervention group
Intervention type: DRUG
Intervention: Exposure of interest (within routine clinical practice):Vitamin B complexes Milgamma® and Milgamma® compositum
Description: Milgamma®: 2 mL injection solution containing thiamin hydrochloride 100 mg, pyridoxine hydrochloride 100 mg, cyanocobalamin 1 mg, lidocaine hydrochloride 20 mg.~Milgamma® compositum: 1 tablet containing benfotiamine 100 mg, pyridoxine hydrochloride 100 mg.
Study NCT02820688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Study NCT02820688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine 1%
Study NCT02820688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular Nerve Block
Description: Ultrasound guided infraclavicular nerve block
Study NCT02820688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.167%
Study NCT02820688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.125%
Study NCT02820688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine 0.66%
Study NCT02820688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine 0.5%
Study NCT02820688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: All nerve blocks will be performed with ultrasound guidance
Study NCT00194727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
Study NCT00194727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
Study NCT00318370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab
Description: Weekly Farletuzumab infusions Dose dependent on dosing group
Study NCT00318370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemo Plus Far
Description: Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
Study NCT05933798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICOPE
Description: The ICOPE approach with locally adapted care pathways was implemented by trained integrated care managers (ICMs) advised by multi-disciplinary teams, delivered in primary care settings
Study NCT05933798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the Control Group would have their care plan after assessment and seek health and care services as usual without additional advice or support on implementing the care plan
Study NCT02275520 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NIO Adult device
Description: IO access-1
Study NCT02275520 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bone Iniection Gun
Description: IO access-2
Study NCT02275520 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EZ-IO
Description: IO access-3
Study NCT02275520 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Jamshidi Intraosseous Needle
Description: IO access-4
Study NCT02275520 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cook Intraosseous Needle
Description: IO access-5
Study NCT01873807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDA
Description: Idarubicin: 15mg/m2/d: -8->-6d
Study NCT01873807 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TBI
Description: TBI: 4.5 Gy/d, -5d, -4d
Study NCT01873807 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: TBI
Description: TBI: 4.5 Gy/d, -5d, -4d
Study NCT01873807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX
Description: CY:60mg/kg/d, -3d, -2d
Study NCT01873807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX
Description: CY:60mg/kg/d, -3d, -2d
Study NCT01873807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: VP-16: 15mg/kg, -2d, -1d
Study NCT01873807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VP-16
Description: VP-16: 15mg/kg, -2d, -1d
Study NCT02938507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1 solabegron
Study NCT02938507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2 solabegron
Study NCT02448914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIGEL
Description: All patients will receive TRIGEL. Treatment order is determined by randomization.
Study NCT02448914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duodopa
Description: All patients will receive Duodopa. Treatment order is determined by randomization.
Study NCT04707378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation(rTMS)
Description: Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
Study NCT04707378 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation(rTMS)
Description: Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
Study NCT01405378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot therapy and transcranial direct current stimulation
Description: Administration of Robot Therapy:~Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:~Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2).
Study NCT01405378 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Robot therapy and transcranial direct current stimulation
Description: Administration of Robot Therapy:~Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:~Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2).
Study NCT02480504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention intermittent energy restriction
Description: Randomized clinical trial
Study NCT02480504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous energy restriction
Study NCT03983460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Each single used prefilled syringe contains 300 mg of Dupilumab in 2 mL solution (150mg/mL) Dupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signaling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
Study NCT03983460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized TCS treatment
Description: Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05% cream), a very potent topical corticosteroid. TCS treatment will be associated with a personal therapeutic education for treatment optimization.
Study NCT03983460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: Four skin biopsies (5 mm diameter) and ten microbiopsies (2 \& 3 mm diameter) will be performed according the following schedule:~* Day 0~  * a 5 mm section biopsy from a non-lesional skin~ * a 5 mm section biopsy from an active lesion~ * a 3 mm section microbiopsies from a non-lesional skin~ * a 3 mm section microbiopsies from an active lesion~ * a 2 mm section microbiopsies from a non-lesional skin~ * a 2 mm section microbiopsies from an active lesion~* Day 28~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion~* Day 168~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non-lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion
Study NCT03983460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsies
Description: Four skin biopsies (5 mm diameter) and ten microbiopsies (2 \& 3 mm diameter) will be performed according the following schedule:~* Day 0~  * a 5 mm section biopsy from a non-lesional skin~ * a 5 mm section biopsy from an active lesion~ * a 3 mm section microbiopsies from a non-lesional skin~ * a 3 mm section microbiopsies from an active lesion~ * a 2 mm section microbiopsies from a non-lesional skin~ * a 2 mm section microbiopsies from an active lesion~* Day 28~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion~* Day 168~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non-lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion
Study NCT01154816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given orally
Study NCT01154816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01154816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03599271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Coated Device
Description: 3000 mcg mometasone furoate-coated sinus dilation device